Immunopathogenesis, molecular phenotyping, and host-directed interventions for severe pediatric Mycoplasma pneumoniae...

Area of Science:

• Immunology
• Infectious Diseases
• Pulmonology

Background:

• Severe Mycoplasma pneumoniae pneumonia (SMPP) is a significant clinical issue, worsened by macrolide-resistant strains (MRMP) and viral co-infections.
• Disease progression is driven by immune dysregulation, including NLRP3 inflammasome activation and pathogenic Th17 cell hyperactivation.
• Antibiotic use can disrupt the gut-lung axis, impairing beneficial bacteria and exacerbating lung injury.

Purpose of the Study:

• To review the immune mechanisms underlying SMPP.
• To explore the impact of macrolide resistance and co-infections on disease severity.
• To propose a translational framework integrating diagnostics and host-directed therapies (HDTs).

Main Methods:

• Review of current literature on SMPP pathogenesis and treatment.
• Analysis of immune pathways involved in severe pneumonia.
• Integration of multi-omics data and clinical biomarkers for risk stratification.
• Evaluation of host-directed therapies (HDTs) for managing SMPP.

Main Results:

• SMPP pathogenesis involves innate and adaptive immune hyperactivation, not just direct pathogen injury.
• Systemic azithromycin can negatively impact the gut-lung axis and Treg function.
• Machine-learning nomograms integrating multi-omics data show promise for early risk prediction.
• HDTs like corticosteroids and anticoagulants can mitigate excessive inflammation and hypercoagulability.

Conclusions:

• Understanding SMPP requires focusing on immune-mediated mechanisms and the gut-lung axis.
• Precision diagnostics are crucial for identifying high-risk patients.
• Targeted HDTs offer a promising strategy to improve clinical outcomes in severe pneumonia.